Drug notes:
Undisclosed RD pain
About:
Lycia Therapeutics is developing tools to degrade extracellular proteins exploiting knowledge of lysosomes. Lysosomes are cellular organelles that are hubs for protein degradation. Using their Lysosomal Targeting Chimera (LYTAC) platform, Lycia is hijacking the endogenous lysosomal trafficking shuttle to target the untapped extracellular proteome. The LYTAC platform can be extended to both board-based and tissue-specific targeting enabling several therapeutic modalities. Lycia is advancing an undisclosed discovery pipeline of novel LYTAC degraders for clearing protein aggregates and immune complexes, removal of circulating antibodies and degrading challenging membrane targets to treat autoimmune and inflammatory diseases.
Jobs:
Senior Scientist I/II, Antibody Engineering (Phag... South San Francisco|4 days ago
Senior Scientist I, Biology South San Francisco|22 days ago
Scientist I, Antibody Design South San Francisco|25 days ago
Senior Accounting Manager / Assistant Controller South San Francisco|40 days ago
Laboratory Manager South San Francisco|52 days ago
Principal Scientist, Clinical Pharmacologist/Model... South San Francisco|61 days ago
Head of Regulatory Affairs South San Francisco|82 days ago
Research Associate II/Senior Research Associate I,... South San Francisco|88 days ago